Cargando…

Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain

AIMS/INTRODUCTION: Diabetic peripheral neuropathic pain (DPNP) affects the functionality, mood and sleep patterns of patients with diabetes. Mirogabalin, an α(2)δ ligand with a slower dissociation for α(2)δ‐1 versus α(2)δ‐2 subunits, showed efficacy and safety in a randomized, double‐blind, placebo‐...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baba, Masayuki, Matsui, Norimitsu, Kuroha, Masanori, Wasaki, Yosuke, Ohwada, Shoichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232295/ https://www.ncbi.nlm.nih.gov/pubmed/31722446 http://dx.doi.org/10.1111/jdi.13178

Ejemplares similares

Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients
por: Baba, Masayuki, et al.
Publicado: (2019)

Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
por: Baba, Masayuki, et al.
Publicado: (2020)

Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study
por: Baba, Masayuki, et al.
Publicado: (2020)

Long-term safety and efficacy of mirogabalin in Asian patients with postherpetic neuralgia: Results from an open-label extension of a multicenter randomized, double-blind, placebo-controlled trial
por: Kato, Jitsu, et al.
Publicado: (2020)

Mirogabalin for the management of postherpetic neuralgia: a randomized, double-blind, placebo-controlled phase 3 study in Asian patients
por: Kato, Jitsu, et al.
Publicado: (2019)

Long-Term Safety and Efficacy of Mirogabalin for Central Neuropathic Pain: A Multinational, Phase 3, 52-Week, Open-Label Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
por: Tetsunaga, Tomoko, et al.
Publicado: (2020)

Therapeutic Effect of Mirogabalin on Peripheral Neuropathic Pain due to Lumbar Spine Disease
por: Kim, Kyongsong, et al.
Publicado: (2021)

Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Correction to: Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study
por: Nikaido, Takuya, et al.
Publicado: (2022)

Mirogabalin for Central Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Asia
por: Ushida, Takahiro, et al.
Publicado: (2023)

Mirogabalin, a selective gabapentinoid for managing neuropathic pain—A curtain raiser
por: Nair, Abhijit
Publicado: (2022)

The Clinical Application and Progress of Mirogabalin on Neuropathic Pain as a Novel Selective Gabapentinoids
por: Tang, Hui, et al.
Publicado: (2023)

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies
por: Brown, Karen, et al.
Publicado: (2018)

Frequency of Adverse Drug Reactions and Analgesic Effects of Mirogabalin during Treatment of Peripheral Neuropathic Pain: A Retrospective Clinical Investigation
por: Inage, Kazuhide, et al.
Publicado: (2020)

Mirogabalin Decreases Pain-like Behaviours and Improves Opioid and Ketamine Antinociception in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2022)

Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin
por: Yamanaka, Takuya, et al.
Publicado: (2022)

Switching From Pregabalin to Mirogabalin in Patients with Peripheral Neuropathic Pain: A Multi-Center, Prospective, Single-Arm, Open-Label Study (MIROP Study)
por: Kimura, Yoshiyuki, et al.
Publicado: (2021)

Somnolence and Dizziness During Mirogabalin Treatment in Patients With Neuropathic Pain Related to Lumbar Disease Who Switched From Pregabalin: A Retrospective Study
por: Akazawa, Tsutomu, et al.
Publicado: (2021)

Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study)
por: Misawa, Sonoko, et al.
Publicado: (2023)

Mirogabalin vs pregabalin for chemotherapy-induced peripheral neuropathy in pancreatic cancer patients
por: Sugimoto, Mitsuru, et al.
Publicado: (2021)

Mirogabalin and emerging therapies for diabetic neuropathy
por: Javed, Saad, et al.
Publicado: (2018)

Combination of Mirogabalin and Duloxetine Attenuates Peripheral Neuropathy by Eribulin: A Novel Case Report
por: Saito, Yoshitaka, et al.
Publicado: (2022)

Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain
por: Cocito, Dario, et al.
Publicado: (2014)

Mirogabalin treatment of postoperative neuropathic pain after thoracic surgery: study protocol for a multicenter, randomized, open-label, parallel-group, interventional trial
por: Doi, Ryoichiro, et al.
Publicado: (2021)

Abuse potential of mirogabalin in recreational polydrug users
por: Mendell, Jeanne, et al.
Publicado: (2019)

A Probable Case of Mirogabalin-Induced Neutropenia
por: Takahashi, Saeko, et al.
Publicado: (2020)

Mirogabalin: could it be the next generation gabapentin or pregabalin?
por: Kim, Jae-Yeon, et al.
Publicado: (2021)

Comment on “Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain”
por: Kriek, R.
Publicado: (2014)

Mirogabalin as a Novel Gabapentinoid for the Treatment of Chronic Pain Conditions: An Analysis of Current Evidence
por: Chen, Eric Y., et al.
Publicado: (2021)

Effects of Mirogabalin on Hyperalgesia and Chronic Ocular Pain in Tear-Deficient Dry-Eye Rats
por: Kikuchi, Kasumi, et al.
Publicado: (2023)

Peripheral mechanisms of peripheral neuropathic pain
por: Pacifico, Paola, et al.
Publicado: (2023)

Mirogabalin Decreases Pain-like Behaviors by Inhibiting the Microglial/Macrophage Activation, p38MAPK Signaling, and Pronociceptive CCL2 and CCL5 Release in a Mouse Model of Neuropathic Pain
por: Zajączkowska, Renata, et al.
Publicado: (2023)

Toward Composite Pain Biomarkers of Neuropathic Pain—Focus on Peripheral Neuropathic Pain
por: Diaz, Monica M., et al.
Publicado: (2022)

Analgesic characteristics of a newly developed α(2)δ ligand, mirogabalin, on inflammatory pain
por: Komatsu, Shuji, et al.
Publicado: (2021)

A Comprehensive Drug Safety Evaluation of Pregabalin in Peripheral Neuropathic Pain
por: Freynhagen, Rainer, et al.
Publicado: (2015)

Pharmacokinetics and Safety of a Single Oral Dose of Mirogabalin in Japanese Subjects With Varying Degrees of Renal Impairment
por: Kato, Manabu, et al.
Publicado: (2017)

Chemotherapy induced peripheral neuropathic pain
por: Park, Hue Jung
Publicado: (2014)

Neuropathic pain in hereditary peripheral neuropathy
por: Jeong, Na Young, et al.
Publicado: (2013)

Comparison of the Efficacy and Safety of Duloxetine and Gabapentin in Diabetic Peripheral Neuropathic Pain: A Meta-Analysis
por: Jiang, Lanying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v5gom05pnvka6k6c828q0lhd8d